Alexion Pharmaceuticals (ALXN) 139.61 $ALXN
Researchers to Present New Data on Asfotase Alfa in Infants and Juveniles with Hypophosphatasia at the Joint Meeting of the Pediatric Academic Societies and the Asian Society for Pediatric Research
Business Wire - Fri Apr 11, 5:11PM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present new data from the extension phase of two clinical studies examining the long-term efficacy and safety of asfotase alfa in infants and juveniles with hypophosphatasia (HPP) at the joint meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research, which takes place May 3-6, 2014 in Vancouver, B.C., Canada. The meeting will also feature the presentation of results from a retrospective natural history study of patients with perinatal and infantile HPP.
Update on BioLineRx's BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 5:10PM CDT
BioLineRx announced that Prof. Arnon Nagler was given the final regulatory approval to evaluate BL-8040 in a phase I/II study for the treatment of CML.
Encouraging Results on Gilead's Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:15PM CDT
Gilead announced encouraging results from two phase II studies and a compassionate access study on Sovaldi.
Positive Data on Biogen/Sobi's Eloctate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 10:40AM CDT
Biogen/Sobi reported positive top-line data on their hemophilia A candidate, Eloctate from a phase III pediatric study (Kids A-LONG).
Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:39AM CDT
Rite Aid Corporation was a big mover last session, as its shares rose over 8% on the day.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Why Alexion Pharmaceuticals, Gilead Sciences, and Monster Beverage Corporation Are Today’s 3 Worst S
John Divine, The Motley Fool - Motley Fool - Thu Apr 10, 7:02PM CDT
After about seven out of every 10 stocks added ground yesterday, I opened my evening article with a simple sentence: "It was tough ," I said, "to lose money in the stock market today." Nothing could be further from the truth on Thursday, when the ...
Stocks Fall In Higher Volume; Alexion, Gilead Drop 7%
at Investor's Business Daily - Thu Apr 10, 4:05PM CDT
The major averages erased two days of gains Thursday as the tech-heavy Nasdaq recorded its biggest single-day decline since November 2011. The Nasdaq plunged 3.1%, led by former leaders in the software, solar-energy and biotech industries. The S&P...
Market Hustle: Nasdaq Sees Biggest Falls Since 2011
at The Street - Thu Apr 10, 3:17PM CDT
U.S. markets are lower Thursday despite data showing an improvement in labor market conditions. Stocks relinquish some of Wednesday's gains when markets jumped on the dovish tone struck by the minutes of the latest Federal Reserve meeting. Tech...
Oh Biotech, You Are a Cruel Bitch
at The Street - Thu Apr 10, 12:09PM CDT
Wednesday's mini rally was a head fake, leading to more selling Thursday.
Alexion Pharmaceuticals to Report First Quarter 2014 Results on Thursday, April 24, 2014
Business Wire - Thu Apr 10, 9:00AM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2014 on Thursday, April 24, 2014 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio web cast on Thursday, April 24, 2014, at 10:00 a.m. Eastern Time (ET).
3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 10, 8:22AM CDT
The price correction in the biotech sector provides an opportunity to invest in stocks that are a combination of strong fundamentals and a favorable Zacks Rank.
Nasdaq Up 1.7%; Bed, Bath & Beyond Sinks After Hours
at Investor's Business Daily - Wed Apr 09, 4:13PM CDT
The major averages climbed more than 1% Wednesday, as more earnings reports came out after the closing bell. The Nasdaq led the way, climbing 1.7%. The Dow Jones industrial average and S&P 500 each rose 1.1%. But NYSE and Nasdaq volume was...
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 5.55% Gain
Comtex SmarTrend(R) - Wed Apr 09, 3:47PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $147.35 to a high of $156.31. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $153.90 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Alexion, Biogen Among Leading Big-Cap Biotechs
at Investor's Business Daily - Wed Apr 09, 7:02AM CDT
Growth stocks are taking a hit now that the market is in a correction. Biotechs saw a recent sell-off over concerns that the sector was overheating, but biotechs and medical stocks are among leading big-cap stocks. IBD's Big Cap Screen of the Day...
EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 6:00PM CDT
The EPO has upheld Alnylam's McSwiggen patent in oral opposition proceedings in Germany.
Encouraging Pre-Clinical Data from Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:40PM CDT
Celldex announced encouraging results from preclinical studies on its antibody drug conjugate, CDX-014.
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:00PM CDT
Intercept Pharmaceuticals shares fell 9.61% after the company priced a public offering of 1 million shares of its common stock at $320.00 per share.
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Researchers to Present New Data on Asfotase Alfa in Infants and Juveniles with Hypophosphatasia at the Joint Meeting of the Pediatric Academic Societies and the Asian Society for Pediatric Research
Business Wire - Fri Apr 11, 5:11PM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present new data from the extension phase of two clinical studies examining the long-term efficacy and safety of asfotase alfa in infants and juveniles with hypophosphatasia (HPP) at the joint meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research, which takes place May 3-6, 2014 in Vancouver, B.C., Canada. The meeting will also feature the presentation of results from a retrospective natural history study of patients with perinatal and infantile HPP.
Update on BioLineRx's BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 5:10PM CDT
BioLineRx announced that Prof. Arnon Nagler was given the final regulatory approval to evaluate BL-8040 in a phase I/II study for the treatment of CML.
Encouraging Results on Gilead's Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:15PM CDT
Gilead announced encouraging results from two phase II studies and a compassionate access study on Sovaldi.
Positive Data on Biogen/Sobi's Eloctate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 10:40AM CDT
Biogen/Sobi reported positive top-line data on their hemophilia A candidate, Eloctate from a phase III pediatric study (Kids A-LONG).
Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:39AM CDT
Rite Aid Corporation was a big mover last session, as its shares rose over 8% on the day.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Why Alexion Pharmaceuticals, Gilead Sciences, and Monster Beverage Corporation Are Today’s 3 Worst S
John Divine, The Motley Fool - Motley Fool - Thu Apr 10, 7:02PM CDT
After about seven out of every 10 stocks added ground yesterday, I opened my evening article with a simple sentence: "It was tough ," I said, "to lose money in the stock market today." Nothing could be further from the truth on Thursday, when the ...
Stocks Fall In Higher Volume; Alexion, Gilead Drop 7%
at Investor's Business Daily - Thu Apr 10, 4:05PM CDT
The major averages erased two days of gains Thursday as the tech-heavy Nasdaq recorded its biggest single-day decline since November 2011. The Nasdaq plunged 3.1%, led by former leaders in the software, solar-energy and biotech industries. The S&P...
Market Hustle: Nasdaq Sees Biggest Falls Since 2011
at The Street - Thu Apr 10, 3:17PM CDT
U.S. markets are lower Thursday despite data showing an improvement in labor market conditions. Stocks relinquish some of Wednesday's gains when markets jumped on the dovish tone struck by the minutes of the latest Federal Reserve meeting. Tech...
Oh Biotech, You Are a Cruel Bitch
at The Street - Thu Apr 10, 12:09PM CDT
Wednesday's mini rally was a head fake, leading to more selling Thursday.
Alexion Pharmaceuticals to Report First Quarter 2014 Results on Thursday, April 24, 2014
Business Wire - Thu Apr 10, 9:00AM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2014 on Thursday, April 24, 2014 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio web cast on Thursday, April 24, 2014, at 10:00 a.m. Eastern Time (ET).
3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 10, 8:22AM CDT
The price correction in the biotech sector provides an opportunity to invest in stocks that are a combination of strong fundamentals and a favorable Zacks Rank.
Nasdaq Up 1.7%; Bed, Bath & Beyond Sinks After Hours
at Investor's Business Daily - Wed Apr 09, 4:13PM CDT
The major averages climbed more than 1% Wednesday, as more earnings reports came out after the closing bell. The Nasdaq led the way, climbing 1.7%. The Dow Jones industrial average and S&P 500 each rose 1.1%. But NYSE and Nasdaq volume was...
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 5.55% Gain
Comtex SmarTrend(R) - Wed Apr 09, 3:47PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $147.35 to a high of $156.31. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $153.90 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Alexion, Biogen Among Leading Big-Cap Biotechs
at Investor's Business Daily - Wed Apr 09, 7:02AM CDT
Growth stocks are taking a hit now that the market is in a correction. Biotechs saw a recent sell-off over concerns that the sector was overheating, but biotechs and medical stocks are among leading big-cap stocks. IBD's Big Cap Screen of the Day...
EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 6:00PM CDT
The EPO has upheld Alnylam's McSwiggen patent in oral opposition proceedings in Germany.
Encouraging Pre-Clinical Data from Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:40PM CDT
Celldex announced encouraging results from preclinical studies on its antibody drug conjugate, CDX-014.
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:00PM CDT
Intercept Pharmaceuticals shares fell 9.61% after the company priced a public offering of 1 million shares of its common stock at $320.00 per share.
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
